Background and aims:- CXCL5 is a small cytokine belonging to the CXC chemokine family predominantly expressed on epithelial cells . This cytokine stimulates the chemotaxis of neutrophils having angiogenic properties. Small interfering RNAs or antibodies against CXCL5 can suppress tumor growth.CXCL5 is considered a therapeutic target in liver diseases. The aim of our study was to assess CXCL5 serum levels in patients with chronic liver diseases.
Materials and Methods:- CXCL5 serum levels were measured in 60 patients with chronic liver disease and 20 apparently healthy controls. Results:- Serum CXCL5 levels in patients with liver cirrhosis were lower than in healthy controls, and correlated with the hepatic biosynthetic capacity, Child-Pugh and MELD scores. In patients with typical clinical complications of cirrhosis, CXCL5 levels were found to be decreased. CXCL5 levels were correlated with clinical presentation and laboratory parameters.
Conclusions:- serum CXCL5 levels are lower in patients with chronic liver disease, suggesting that CXCL5 might be involved in the pathogenesis of chronic liver disease. CXCL5 could serve as an additional biomarker for hepatic necroinflammation and fibrosis
|
